Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)

Journal of Medicinal Chemistry

Volumn 53, Issue 17, 2010, Pages 6466-6476

  Llinàs Brunet, Montse ^a   Bailey, Murray D ^a   Goudreau, Nathalie ^a   Bhardwaj, Punit K ^a   Bordeleau, Josée ^a   Bös, Michael ^a   Bousquet, Yves ^a   Cordingley, Michael G ^a   Duan, Jiamin ^a   Forgione, Pat ^a   Garneau, Michel ^a   Ghiro, Elise ^a   Gorys, Vida ^a   Goulet, Sylvie ^a   Halmos, Ted ^a   Kawai, Stephen H ^a   Naud, Julie ^a   Poupart, Marc André ^a   White, Peter W ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BI 201335; CILUPREVIR; N [(CYCLOPENTYLOXY)CARBONYL] 3 METHYL VALYL 4 [[8 BROMO 7 METHOXY 2 [2 (PROPANOYLAMINO) 1,3 THIAZOL 4 YL]QUINOLIN 4 YL]OXY] N [1 CARBOXY 2 ETHENYLCYCLOPROPYL] LEVO PROLINAMIDE; N [(CYCLOPENTYLOXY)CARBONYL] 3 METHYL VALYL 4 [[8 BROMO 7 METHOXY 2 [2 [(METHOXYCARBONYL)AMINO] 1,3 THIAZOL 4 YL] QUINOLIN 4 YL)OXY] N (1 CARBOXY 2 ETHENYLCYCLOPROPYL) LEVO PROLINAMIDE; N [(CYCLOPENTYLOXY)CARBONYL] 3 METHYL VALYL N (1 CARBOXY 2 ETHENYLCYCLOPROPYL) 4 [[2 [2 [(3,3 DIMETHYLBUTANOYL)AMINO] 1,3 THIAZOL 4 YL] 7 METHOXYQUINOLIN 4 YL]OXY] LEVO PROLINAMIDE; N [(CYCLOPENTYLOXY)CARBONYL] 3 METHYL VALYL N (1 CARBOXY 2 ETHENYLCYCLOPROPYL) 4 [[7 METHOXY 2 [2 (PROPAN 2 YLAMINO) 1,3 THIAZOL 4 YL]QUINOLIN 4 YL]OXY] LEVO PROLINAMIDE; N [(CYCLOPENTYLOXY)CARBONYL] 3 METHYL VALYL N (1 CARBOXY 2 ETHENYLCYCLOPROPYL) 4 [[7 METHOXY 8 METHYL 2 [2 (PROPANOYLAMINO) 1,3 THIAZOL 4 YL]QUINOLIN 4 YL]OXY] LEVO PROLINAMIDE; NONSTRUCTURAL PROTEIN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SYNTHESIS; HEPATITIS C VIRUS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HUMANS; MALE; MICROSOMES, LIVER; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; REPLICON; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 77956301340     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100690x     Document Type: Article

References (33)

1. Lavanchy, D. The global burden of hepatitis C Liver Int. 2009, 29 (Suppl. 1) 74-81
2. Brown, R. S. Hepatitis C and liver transplantation Nature 2005, 436, 973-978
3. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 1989, 244, 359-362
4. Ghany, M. G.; Strader, D. B.; Thomas, D. L.; Seeff, L. B. Diagnosis, management, and treatment of hepatitis C: an update Hepatology 2009, 49, 1335-1374
5. Moradpour, D.; Penin, F.; Rice, C. M. Replication of hepatitis C virus Nat. Rev. Microbiol. 2007, 5, 453-463
6. Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo J. Virol. 2000, 74, 2046-2051
7. Chen, K. X.; Njoroge, F. G. A review of HCV protease inhibitors Curr. Opin. Invest. Drugs 2009, 10, 821-837
8. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A. M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M. A.; Rancourt, J.; Sentjens, R. E., St; George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C. L.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 2003, 426, 186-189
9. Hinrichsen, H.; Benhamou, Y.; Wedemeyer, H.; Reiser, M.; Sentjens, R. E.; Calleja, J. L.; Forns, X.; Erhardt, A.; Cronlein, J.; Chaves, R. L.; Yong, C. L.; Nehmiz, G.; Steinmann, G. G. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients Gastroenterology 2004, 127, 1347-1355
10. Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y. P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob. Agents Chemother. 2006, 50, 899-909
11. Malcolm, B. A.; Liu, R.; Lahser, F.; Agrawal, S.; Belanger, B.; Butkiewicz, N.; Chase, R.; Gheyas, F.; Hart, A.; Hesk, D.; Ingravallo, P.; Jiang, C.; Kong, R.; Lu, J.; Pichardo, J.; Prongay, A.; Skelton, A.; Tong, X.; Venkatraman, S.; Xia, E.; Girijavallabhan, V.; Njoroge, F. G. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrobial Agents Chemother. 2006, 50, 1013-1020
12. Chen, S. H.; Tan, S. L. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection Curr. Med. Chem. 2005, 12, 2317-2342
13. Prongay, A. J.; Guo, Z.; Yao, N.; Pichardo, J.; Fischmann, T.; Strickland, C.; Myers, J., Jr.; Weber, P. C.; Beyer, B. M.; Ingram, R.; Hong, Z.; Prosise, W. W.; Ramanathan, L.; Taremi, S. S.; Yarosh-Tomaine, T.; Zhang, R.; Senior, M.; Yang, R. S.; Malcolm, B.; Arasappan, A.; Bennett, F.; Bogen, S. L.; Chen, K.; Jao, E.; Liu, Y. T.; Lovey, R. G.; Saksena, A. K.; Venkatraman, S.; Girijavallabhan, V.; Njoroge, F. G.; Madison, V. Discovery of the HCV NS3/4A protease inhibitor (1 R,5 S)- N -[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl] -3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization J. Med. Chem. 2007, 50, 2310-2318
14. Llinas-Brunet, M.; Bailey, M.; Fazal, G.; Goulet, S.; Halmos, T.; Laplante, S.; Maurice, R.; Poirier, M.; Poupart, M. A.; Thibeault, D.; Wernic, D.; Lamarre, D. Peptide-based inhibitors of the hepatitis C virus serine protease Bioorg. Med. Chem. Lett. 1998, 8, 1713-1718
15. Steinkuhler, C.; Biasiol, G.; Brunetti, M.; Urbani, A.; Koch, U.; Cortese, R.; Pessi, A.; De Francesco, R. Product inhibition of the hepatitis C virus NS3 protease Biochemistry 1998, 37, 8899-8905
16. Llinas-Brunet, M.; Bailey, M.; Deziel, R.; Fazal, G.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M. A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease Bioorg. Med. Chem. Lett. 1998, 8, 2719-2724
17. Tsantrizos, Y. S.; Bolger, G.; Bonneau, P.; Cameron, D. R.; Goudreau, N.; Kukolj, G.; LaPlante, S. R.; Llinas-Brunet, M.; Nar, H.; Lamarre, D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection Angew. Chem., Int. Ed. 2003, 42, 1356-1360
18. Llinas-Brunet, M.; Bailey, M. D.; Bolger, G.; Brochu, C.; Faucher, A. M.; Ferland, J. M.; Garneau, M.; Ghiro, E.; Gorys, V.; Grand-Maitre, C.; Halmos, T.; Lapeyre-Paquette, N.; Liard, F.; Poirier, M.; Rheaume, M.; Tsantrizos, Y. S.; Lamarre, D. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061 J. Med. Chem. 2004, 47, 1605-1608
19. Rancourt, J.; Cameron, D. R.; Gorys, V.; Lamarre, D.; Poirier, M.; Thibeault, D.; Llinas-Brunet, M. Peptide-based inhibitors of the hepatitis C virus NS3 protease: Structure-activity relationship at the C-terminal position J. Med. Chem. 2004, 47, 2511-2522
20. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain Biochem. Biophys. Res. Commun. 1967, 27, 157-162
21. Stoltz, J. H.; Stern, J. O.; Huang, Q.; Seidler, R. W.; Pack, F. D.; Knight, B. L. A 28-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061. Toxicol. Pathol., submitted 2010.
22. Venkatraman, S.; Njoroge, F. G. Macrocyclic inhibitors of HCV NS3 protease Expert Opin. Ther. Pat. 2009, 19, 1277-1303
23. Seiwert, S. D.; Andrews, S. W.; Jiang, Y.; Serebryany, V.; Tan, H.; Kossen, K.; Rajagopalan, P. T.; Misialek, S.; Stevens, S. K.; Stoycheva, A.; Hong, J.; Lim, S. R.; Qin, X.; Rieger, R.; Condroski, K. R.; Zhang, H.; Do, M. G.; Lemieux, C.; Hingorani, G. P.; Hartley, D. P.; Josey, J. A.; Pan, L.; Beigelman, L.; Blatt, L. M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob. Agents Chemother. 2008, 52, 4432-4441
24. Lin, T. I.; Lenz, O.; Fanning, G.; Verbinnen, T.; Delouvroy, F.; Scholliers, A.; Vermeiren, K.; Rosenquist, A.; Edlund, M.; Samuelsson, B.; Vrang, L.; de Kock, H.; Wigerinck, P.; Raboisson, P.; Simmen, K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrob. Agents Chemother. 2009, 53, 1377-1385
25. Liverton, N. J.; Carroll, S. S.; DiMuzio, J.; Fandozzi, C.; Graham, D. J.; Hazuda, D.; Holloway, M. K.; Ludmerer, S. W.; McCauley, J. A.; McIntyre, C. J.; Olsen, D. B.; Rudd, M. T.; Stahlhut, M.; Vacca, J. P. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease Antimicrob. Agents Chemother. 2010, 54, 305-311
26. Llinas-Brunet, M.; Bailey, M. D.; Ghiro, E.; Gorys, V.; Halmos, T.; Poirier, M.; Rancourt, J.; Goudreau, N. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors J. Med. Chem. 2004, 47, 6584-6594
27. Faucher, A. M.; Bailey, M. D.; Beaulieu, P. L.; Brochu, C.; Duceppe, J. S.; Ferland, J. M.; Ghiro, E.; Gorys, V.; Halmos, T.; Kawai, S. H.; Poirier, M.; Simoneau, B.; Tsantrizos, Y. S.; Llinas-Brunet, M. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans Org. Lett. 2004, 6, 2901-2904
28. Beaulieu, P. L.; Gillard, J.; Bailey, M. D.; Boucher, C.; Duceppe, J. S.; Simoneau, B.; Wang, X. J.; Zhang, L.; Grozinger, K.; Houpis, I.; Farina, V.; Heimroth, H.; Krueger, T.; Schnaubelt, J. Synthesis of (1 R,2 S)-1-amino-2-vinylcyclopropanecarboxylic acid vinyl-ACCA) derivatives: key intermediates for the preparation of inhibitors of the hepatitis C virus NS3 protease J. Org. Chem. 2005, 70, 5869-5879
29. Unangst, P. C.; Connor, D. T. Synthesis and transformations of 2,6-bis(1,1-dimethylethyl)-4-[2-(thiazolyl)ethenyl]phenols J. Heterocycl. Chem. 1992, 29, 1097-1100
30. Manns, M. P.; Bourliare, M.; Benhamou, Y.; Pol, S.; Bonacini, M.; Trepo, C.; Wright, D.; Berg, T.; Calleja, J. L.; White, P. W.; Stern, J. O.; Steinmann, G.; Yong, C. L.; Kukolj, G.; Scherer, J.; Boecher, W. O. Potency, safety and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J. Hepatol., submitted 2010.
31. Massariol, M. J.; Zhao, S.; Marquis, M.; Thibeault, D.; White, P. W. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins Biochem. Biophys. Res. Commun. 2010, 391, 692-697
32. Thibeault, D.; Bousquet, C.; Gingras, R.; Lagace, L.; Maurice, R.; White, P. W.; Lamarre, D. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061 J. Virol. 2004, 78, 7352-7359
33. Vaillancourt, F. H.; Pilote, L.; Cartier, M.; Lippens, J.; Liuzzi, M.; Bethell, R. C.; Cordingley, M. G.; Kukolj, G. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication Virology 2009, 387, 5-10